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ABSTRACT 
Objective: A large trial published in 2000 concluded that planned vaginal delivery of term breech births is 
associated with high neonatal risks. Because the obstetric practices in that study differed from those in countries 
where planned vaginal delivery is still common, we conducted an observational prospective study to describe 
neonatal outcome according to the planned mode of delivery for term breech births in 2 such countries. 
Study design: Observational prospective study with an intent-to-treat analysis to compare the groups for which 
cesarean and vaginal deliveries were planned. Associations between the outcome and planned mode of delivery 
were controlled for confounding by multivariate analysis. The main outcome measure was a variable that 
combined fetal and neonatal mortality and severe neonatal morbidity. The study population consisted of 8105 
pregnant women delivering singleton fetuses in breech presentation at term in 138 French and 36 Belgian 
maternity units.  
Results: Cesarean delivery was planned for 5579 women (68.8%) and vaginal delivery for 2526 (31.2%). Of the 
women with planned vaginal deliveries, 1796 delivered vaginally (71.0%). The rate of the combined neonatal 
outcome measure was low in the overall population (1.59%; 95% CI [1.33-1.89]) and in the planned vaginal 
delivery group (1.60%; 95% CI [1.14-2.17]). It did not differ significantly between the planned vaginal and 
cesarean delivery groups (unadjusted odds ratio = 1.10, 95% CI [0.75-1.61]), even after controlling for 
confounding variables (adjusted odds ratio = 1.40, 95% CI [0.89-2.23]). 
Conclusion: In places where planned vaginal delivery is a common practice and when strict criteria are met 
before and during labor, planned vaginal delivery of singleton fetuses in breech presentation at term remains a 
safe option that can be offered to women. 
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Vaginal deliveries for breech presentations have long been a topic of debate.1 The Term Breech Trial by Hannah 
et al, published in 2000, confirmed for many physicians that neonatal risks associated with term breech births are 
much higher among planned vaginal deliveries and implied that cesarean deliveries should be systematically 
planned for all such women.2,3
Vaginal delivery of breech infants remains standard practice in France. In 1998, the proportion of planned 
vaginal deliveries among term breech infants here was 51.2%, and 65.1% of this group actually delivered 
vaginally.4 In 2000, the French College of Gynecologists and Obstetricians (CNGOF) defined the optimal 
criteria for deciding to attempt vaginal delivery (Table I).5,6 Although the internal validity of Hannah's trial is 
irrefutable, some aspects raise questions about the extrapolation of its results to other settings. The absolute risk 
of mortality and serious perinatal morbidity for the planned vaginal birth group in countries with low perinatal 
mortality rates was high (5.7%), as was the difference between the 2 groups (14 times higher in the vaginal than 
in the systematic cesarean delivery group). These risks were higher than reported in recent European series.7-11 
Moreover, its obstetric practices appear to differ from those in countries where planned vaginal delivery is still 
offered to a large proportion of women with term breech presentations and satisfied only in part French 
guidelines for planned vaginal delivery. For example, pelvimetry was performed for only a minority of women. 
Management of labor for planned vaginal births also differed from French practices, with major disparities in 
methods of fetal surveillance, criteria for optimal dilatation rate, and duration of active pushing.12 
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Because our objective was to describe neonatal morbidity and mortality for term breech births for the entire 
population and according to the planned mode of delivery in countries where vaginal delivery is standard 
practice, we decided to conduct an observational survey without modifying obstetric practices. 
METHODS 
Patients and study design 
Prospective data collection in maternity units volunteering for the PREMODA (PREsentation et MODe 
d'Accouchement: presentation and mode of delivery) study took place from June 1, 2001, through May 31, 2002, 
in 138 centers in France, for 232,999 births, and from January 1, 2002, through December 31, 2002, in 36 
centers in Belgium, for 31,106 births. The study was approved by the National Commission for Data Protection 
in Paris on May 9, 2001. It included all women giving birth in a participating maternity unit to a singleton fetus 
in breech presentation at term (≥37 weeks' gestation), alive or not. The study did not modify patient 
management. A local investigator in each center was responsible for prospective data collection and monitoring 
data quality. This person forwarded data regularly to the regional and then national coordination offices, which 
also monitored them prospectively. Finally, at the end of the study, the national coordinator (M.C.) visited 20 
randomly selected centers to evaluate data collection. Detailed reports were obtained (and supplemental 
information requested if necessary) for all deaths before discharge and transfers to neonatal intensive or 
intermediate care units. All existing autopsy reports were sought and obtained. All congenital anomalies and 
reasons for hospitalization were coded according to the 10th edition of the International Classification of 
Diseases.13 All deaths before discharge—fetal, neonatal, and postneonatal deaths—were reviewed by an 
independent expert committee (members listed in Appendix) to determine the cause of each death and whether a 
planned cesarean delivery at 39 weeks (as recommended by the CNGOF) might have prevented it. 
Outcomes and factors studied 
The principal outcome measure was a composite variable, similar to that used in the Term Breech Trial2 and 
including fetal and neonatal mortality and serious morbidity. It was defined as fetal or neonatal mortality at less 
than 28 days of age before discharge (excluding lethal congenital anomalies) or 1 or more of the following: birth 
trauma, including subdural hematoma, intracerebral or intraventricular hemorrhage, spinal-cord injury, basal 
skull fracture, peripheral-nerve injury present at discharge, or clinically significant genital injury; seizures 
occurring at less than 24 hours of age; 5-minute Apgar score of less than 4, intubation and ventilation for at least 
24 hours, tube feeding for at least 4 days, or admission to the neonatal intensive care unit for longer than 4 days. 
We examined the case files and recorded the items recommended by the CNGOF as a basis for deciding mode of 
delivery and the elements used for managing and monitoring labor (Table I). All participating centers 
systematically used continuous electronic fetal heart rate monitoring for fetal surveillance. 
Table I- Items recommended by the CNGOF as a basis for deciding mode of delivery (2000 CNGOF guidelines 
[www.cngof. asso.fr]) and the elements used for describing management and monitoring labor 
Items recommended by the CNGOF as a basis for deciding 
mode of delivery 
Normal pelvimetry 
No hyperextension of fetal head (checked with ultrasonography) 
Fetal weight estimated between 2500 and 3800 g  
(with clinical and ultrasound examinations) 
Frank breech 
Continuous electronic fetal heart-rate monitoring for fetal surveillance during labor 
Patient's informed consent 
Elements used for describing management and monitoring labor 
Induction or augmentation of labor with intravenous oxytocin 
Lack of progress 
Duration of the first stage of labor 
Duration of passive and active phases of the second stage 
Station at beginning of active pushing 
Methods of vaginal breech delivery (spontaneous, assisted systematically, assisted for 
difficulty in delivery, manual or instrumental extraction) 
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Sample size 
We calculated that at least 4640 women had to be enrolled for us to be able to show a significant doubling of 
neonatal risk in the planned vaginal delivery group compared with the planned cesarean group (2% vs 1%; type 
II error = 0.20, 2-sided type I error of 0.05), with a planned cesarean rate of 50% for the entire population. 
Definition of the study groups 
Our objective was to compare neonatal status according to the antenatal decision about mode of delivery. The 
planned cesarean delivery group was made up of the cesarean deliveries before labor, those planned before but 
performed after labor began and the vaginal deliveries when a cesarean delivery had been planned. All other 
women were considered to belong to the planned vaginal delivery group. 
 
Table II- Maternal and obstetric characteristics in the planned vaginal and planned cesarean delivery groups 
 Planned vaginal delivery N 
= 2,526  
n (%) 
Planned caesarean section N 




   ≤21 y 164 (6.6) 287 (5.2) .02 
   22-34 y 1941 (77.9) 4301 (77.8)  
   ≥35 y 387 (15.5) 939 (17.0)  
Geographic origin 
   French 1802 (72.0) 3756 (67.9) <.001 
   Belgian 147 (5.9) 638 (11.5)  
   European 112 (4.5) 253 (4.6)  
   North African 185 (7.4) 339 (6.1)  
   Subsaharan African 64 (2.6) 127 (2.3)  
   Other 88 (3.5) 172 (3.1)  
   Unspecified 102 (4.1) 249 (4.5)  
Educational level 
   Primary school or less 98 (3.9) 179 (3.2) .005 
   Middle school 461 (18.3) 898 (16.1)  
   Secondary school 357 (14.1) 916 (16.4)  
   Postsecondary 851 (33.7) 1825 (32.7)  
  Not specified 759 (30.1) 1761 (31.6)  
Parity 
   Nullipara 1187 (47.2) 3249 (58.7) <.001 
   Primipara 754 (30.0) 1487 (26.8)  
   > 1 para 573 (22.8) 805 (14.5)  
Uterine scar 
   No 2451 (98.1) 4620 (83.4) <.001 
   Single Scar 45 (1.8) 742 (13.4)  
   Two or more scars 3 (0.1) 175 (3.2)  
Type of breech: 
   Complete breech 750 (29.7) 1530 (27.4) <.001 
   Frank breech 1669 (66.1) 3052 (54.7)  
   Unspecified 107 (4.2) 997 (17.9)  
Size of the maternity ward (births per y) 
   <1000 239 (9.5) 682 (12.2) <.001 
   ≥1000 and <2000 1093 (43.3) 2450 (43.9)  
   ≥2000 1194 (47.2) 2447 (43.9)  
Type of the maternity ward 
   Public 2035 (80.6) 1227 (22.0) .009 
   Private 491 (19.4) 4352 (78.0)  
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Analysis 
We first described the mode of delivery, cesarean indications and all fetal and neonatal deaths according to cause 
of death and mode of delivery. Obstetric practices related to the criteria for mode of delivery and the methods for 
monitoring labor were examined for the entire population, and the 2 groups compared for the neonatal morbidity 
criteria. Finally, all the factors associated with the principal outcome measure with a P value less than .10 were 
included in a logistic regression model to obtain an adjusted odds ratio for planned vaginal delivery. 
The groups were compared with a χ2 test (or exact Fisher test if required) for the analysis of categorical 
variables, and a 2-sided P value of less than .05 was defined as a significant difference. Statistical comparisons 
and logistic regressions were performed with Stata software version 8 (Stata Corp, College Station, TX). 
 
Table III- Mode of delivery, birth weight, gestational age, and performance of a pelvimetry in the planned 
vaginal and planned cesarean delivery groups 
 Planned vaginal delivery N 
= 2526  
n (%) 
Planned cesarean section N 
= 5579  
n (%) 
P 
Mode of delivery 
   Cesarean before labor 0 4791 (85.8) <.001 
   Cesarean during labor 732 (29.0) 757 (13.6)  
   Vaginal delivery 1794 (71.0) 31 (0.6)  
Reasons for cesarean before labor 
   Breech 0 2083 (43.5)  
   Fetopelvic disproportion 0 906 (18.9)  
   Uterine scar 0 535 (11.2)  
   Patient's request 0 468 (9.8)  
   Fetal condition 0 182 (3.8)  
   Maternal associated disease 0 174 (3.6)  
   Other reasons 0 359 (7.5)  
   Unspecified 0 84 (1.7)  
Reasons for cesarean during labor 
   Planned cesarean section 0 757  
   Failure to progress 185 (25.3) 0  
   FHR anomalies 101 (13.8) 0  
   Failure to progress and FHR anomalies 77 (10.5) 0  
   Diverse other reasons 332 (45.3) 0  
   Unspecified 37 (5.1) 0  
Gestational age 
   37 wks 289 (11.5) 668 (12.0) <.001 
   38 wks 497 (19.7) 2094 (37.6)  
   39 wks 715 (28.3) 1984 (35.6)  
   40 wks 688 (27.3) 559 (10.0)  
   ≥41 wks 336 (13.3) 267 (4.8)  
Birth weight 
   <2500 g 154 (6.1) 293 (5.3) <.001 
   ≥2500 and <3000 g 758 (30.1) 1604 (28.8)  
   ≥3000 and <3500 g 1104 (43.7) 2351 (42.1)  
   ≥3500 and <4000 g 443 (17.6) 1090 (19.6)  
   ≥4000 g 63 (2.5) 235 (4.2)  
Birth weight for gestational age* 
   <10th 142 (5.7) 228 (4.1) <.001 
   ≥10th and ≤ 90th 2142 (86.2) 4610 (83.3)  
   >goth 202 (8.1) 700 (12.6)  
Pelvimetry performed 2064 (82.5) 3044 (55.5) <.001 
* Birth weight for gestational age was defined by birth weight <l0th, 10th-90th, and >90th percentile of the birth weight distribution curve of 
Lubchenco et al.25
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RESULTS 
During the 12-month study period, 1,133 women were included in Belgium and 6,972 in France, for a total of 
8,105 women delivering singleton fetuses in breech presentation at term. During the inclusion period, 264,105 
births took place in the 174 centers, for a rate of singleton term fetuses in breech presentation of 3.1% 
(8,105/264,105). Tables II and III report the general maternal and obstetric characteristics for the planned vaginal 
and cesarean delivery groups. The rate of planned cesarean delivery for the entire sample was 68.8% (n = 5,579) 
and differed widely between centers (median [10th-90th percentile] = 69.8% [47.8%-89.0%]). Breech 
presentation was the only reason for 43.5% of the cesarean deliveries before labor (n = 2,083). The rate of 
cesarean delivery during labor for the entire sample was 18.4% (n = 1,489), nearly half because women for 
whom cesarean delivery was planned went into labor before the date planned (n = 757, 50.7%). In all, 1,825 
women (22.5%) gave birth vaginally. 
 
Table IV- Fetal and neonatal mortality and morbidity (excluding lethal congenital anomalies) in the planned 
vaginal delivery and planned caesarean section groups 
 Planned vaginal delivery 
N = 2502  
n (% 95% CI) 
Planned caesarean section 
N = 5573  
n (% 95% CI) 
OR [95% CI] 
5-min Apgar 
   <4* 4 (0.16 [0.04-0.41]) 1 (0.02 [0.00-0.10]) 8.92 [1.00-79.8] 
   <7 37 (1.48 [1.04-2.03]) 26 (0.46 [0.30-0.68]) 3.20 [1.93-5.30] 
Total injuries 45 (1.80 [1.31-2.40]) 26 (0.46 [0.30-0.68]) 3.90 [2.40-6.34] 
   Fracture clavicle 15 5  
   Fracture of humerus 2 0  
   Other fractures 0 4  
   Brachial plexus injuries* 5 4  
   Parietal skull fracture* 1 0  
   Sternocleidomastoid injury 3 0  
   Cutaneous wound with suture 1 4  
   Hematoma, contusions 13 5  
   Other injuries 5 4  
Transfer to NICU 54 (2.16 [1.63-2.81]) 91 (1.63 [1.32-2.00]) 1.33 [0.94-1.86] 
NICU >4 days* 23 (0.92 [0.58-1.38]) 53 (0.95 [0.71-1.24]) 0.97 [0.59-1.58] 
Intubation 26 (1.04 [0.68-1.52]) 32 (0.57 [0.39-0.81]) 1.82 [1.08-3.06] 
Persistent after the first 24 h* 10 (0.40 [0.19-0.73]) 21 (0.38 [0.23-0.58]) 1.06 [0.50-2.26] 
Transfer to NICU 140 (5.60 [4.73-6.57]) 280 (5.04 [4.47-5.68]) 1.12 [0.91-1.38] 
Convulsions 4 (0.16 [0.04-0.41]) 7 (0.13 [0.05-0.26]) 1.27 [0.37-4.33] 
Continued after first 24 h* 1 (0.04 [0.00-0.22]) 4 (0.07 [0.02-0.18]) 0.56 [0.06-4.98] 
Parenteral or tubal feeding >4 days* 15 (0.60 [0.34-0.98]) 32 (0.57 [0.39-0.81]) 1.04 [0.56-1.93] 
IVH 1 (0.04 [0.00-0.22]) 2 (0.04 [0.004-0.13]) 1.11 [0.10-12.28] 
   Grade 1 0 1  
   Grade 2 1 1  
Fetal death* 2 (0,08 [0.009-0.28]) 7 (0,13 [0.05-0.26]) 0.64 [0.13-3.06] 
Neonatal death* 0 1 (0.02 [0.00-0.10]) — 
Fetal and neonatal mortality or serious 
neonatal morbidity 
40 (1.60 [1.14-2.17]) 81 (1.45 [1.16-1.81]) 1.10 [0.75-1.61] 
Frequencies of morbidity criteria are calculated for live births. Intention-to-treat analysis of morbidity according to the planned mode of 
delivery includes 8075 subjects rather than 8105 (difference = 30) because this analysis excludes the 17 neonatal deaths with lethal 
malformations (6 planned vaginal delivery and 11 planned cesarean sections), the 4 in utero deaths with lethal malformations (all vaginal 
delivery), the pregnancy termination because of severe congenital CMV infection (vaginal delivery) and the 8 in utero deaths without a 
decision about mode of delivery (all vaginal delivery) (17 + 4+ 1 + 8 = 30). NICU, Neonatal intensive care unit; IVH, intracerebral 
ventricular hemorrhage; CMV, cytomegalovirus.  
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The combined stillbirth and neonatal mortality rate was 3.9 per thousand births (22 fetal deaths and 10 neonatal 
deaths). In all, 6 of the 22 fetal deaths, and 17 of the 18 neonatal or postneonatal deaths before discharge were 
associated with a lethal congenital anomaly. Two of these deaths occurred in the delivery room, one associated 
with severe pontocerebellar atrophy and the other with severe ichthyosis. The only neonatal death not associated 
with a lethal congenital anomaly was sudden and unexplained, at home on day 15, and no cause was found. 
Seven fetal deaths occurred at or after 39 weeks. The independent expert committee considered that 3 could have 
been avoided if the woman had received adequate antenatal care and agreed to a planned cesarean delivery at 39 
weeks. In the first case, a woman who had already 2 previous caesarean deliveries refused 1 here, despite the 
recommendation of the obstetric team: when she came to the maternity ward at a term of 39 weeks + 3 days for 
uterine contractions, in utero fetal death was diagnosed and remained unexplained. The second case involved a 
woman, gravida 2, para 1, with a previous cesarean delivery and normal prenatal care. Trial of vaginal delivery 
was planned but uterine rupture at 40 weeks resulted in an emergency caesarean delivery; the infant was 
stillborn. In the third case, the mother (gravida 7, para 5, and 42 years of age) sought prenatal care only during 
the second half of pregnancy, term was uncertain, and the file included no decision about mode of delivery. 
When she arrived at the maternity ward in labor at a term of 39 weeks + 6 days, fetal death was diagnosed and 
remained unexplained. 
Fetal or neonatal death or serious neonatal morbidity without lethal congenital anomalies was reported for 129 
infants, or 1.59% of the entire sample (95% CI [1.33-1.89]) and for 40 infants in the planned vaginal delivery 
group (1.60% 95% CI [1.14-2.17]). Table IV shows the perinatal outcome according to planned mode of 
delivery, after excluding lethal congenital anomalies. The groups did not differ significantly for the combined 
outcome of fetal or neonatal mortality or serious morbidity (odds ratio [OR] = 1.10, 95% CI [0.75-1.61]. Of the 
criteria included in this combined variable, only a 5-minute Apgar score less than 4 was significantly more 
frequent in the planned vaginal group (n = 4 vs n = 1, OR = 8.9, 95% CI [1.00-79.8]). Of the other individual 
outcomes, the following were significantly more frequent in the planned vaginal than in the planned cesarean 
group: 5-minute Apgar score less than 7 (OR = 3.2, 95% CI [1.9-5.3]), total injuries (OR = 3.9, 95% CI [2.4-
6.3]), and intubation (OR = 1.8, 95% CI [1.08-3.1]). 
Factors significantly associated with fetal or neonatal mortality or severe morbidity with a threshold less than 
0.10 were maternal age, educational level, parity, gestational age at delivery, birth weight, performance of 
pelvimetry, status of the maternity ward, and cesarean delivery before labor for fetal condition. After controlling 
for risk factors, the risk of fetal or neonatal mortality or serious morbidity was not significantly different among 
the planned vaginal and cesarean groups (adjusted OR = 1.40 95%CI [0.89-2.23]). 
Table V reports management during labor and delivery for the vaginal deliveries. 
Comment 
This prospective study showed a global risk of 1.59% (95% CI [1,33-1,89]) for fetal or neonatal mortality or 
serious neonatal morbidity among the overall population of singleton term breech infants. Vaginal delivery for 
breech presentation at term remained a common practice in 2001 through 2002 in France and Belgium (22.5%). 
Under the standard practice conditions, neonatal outcome was not significantly poorer among infants with 
planned vaginal than with planned cesarean deliveries. 
The participating maternity units account for a substantial portion of the births in France (29.3%) (232,999/ 
796,000) and French-speaking Belgium (47.9%) (31,106/ 65,000). Inclusion of all term breech infants in each 
unit during the study period ensures that results represent current practices in these units. We included an 
average of 60 women per center during the study year and systematically recorded all available information 
about antenatal decisions as well as neonatal mortality and morbidity. The methodology we used allows us to 
meet the primary objectives of PREMODA, to describe practices on a daily basis for the entire population, and 
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Table V- Management of Labor and delivery for vaginal deliveries 
 N = 1,825, N (%) 
Induction of labor 163 (8.9) 
First method used for induction: 
   Prostaglandins 45 (28.7) 
   Oxytocin 111 (70.7) 
   Mechanical means 1 (0.6) 
Oxytocin augmentation without labor induction  1107 (74.1) 
Lack of progress in dilatation 
   None 1534 (87.2) 
   At least 1 failure to progress > 1 h 144 (8.2) 
   At least 1 failure to progress > 2 h 67 (3.8) 
   At least 2 episodes of failure to progress >l h     14 (0.8) 
Duration of first stage of labor between 5 and 10 cm dilatation 
   <4 h 1208 (66.2) 
   4-6 h 248 (13.6) 
   ≥7 h 25 (1.4) 
Unspecified 344 (18.8) 
Duration of passive phase of second stage of labor 
   <30 min 1,093 (63.9) 
   30-60 min 308 (18.0) 
   ≥60 min 310 (18.1) 
Duration of active phase of second stage of labor 
   <30 min 1671 (94.0) 
   30-60 min 103 (5.8) 
   ≥60 min 4 (0.2) 
Station at beginning of active pushing  
   High 63 (3.6) 
   Mid 507 (28.5) 
   Low 1,017 (57.1) 
   Unspecified 195 (10.8) 
Maneuvers during delivery  
   None 633 (35.3) 
   Systematic* 543 (30.3) 
   For extended arms 226 (12.6) 
   For entrapped fetal head 71 (4.1) 
   For extended arms and entrapped 109 (6.1) 
       fetal head  
Other 151 (8.4) 
Maneuvers and forceps for entrapped fetal head 57 (3.2) 
Difficulties during expulsion 87 (4.8) 
Senior obstetrician present at delivery 1657 (92.3) 
* Many teams have a set of maneuvers they use routinely for breech deliveries, even when no difficulties arise. 
 
Most large studies of term breech deliveries are retrospective and based on registry data. They generally report 
considerably increased neonatal risks in the vaginal delivery group.1,14-16 The many patients included  in  such  
studies  allow  statistically  significant comparisons but their results are difficult to interpret because of the 
questionable validity and sparseness of the antenatal and postnatal information. In the PRE-MODA study, data 
were collected to answer the question about the association between mode of delivery and serious neonatal 
morbidity or mortality. Thus, we meticulously examined causes of death and morbidity. We noted neonatal 
conditions, including genetic syndromes and metabolic diseases, which were diagnosed days, or even weeks 
after birth, and required specific research. Of the 129 cases of fetal or neonatal death or severe neonatal 
morbidity, 33 (25.6%) had nonlethal major or minor malformations that sometimes explained the abnormal 
neonatal condition. Similarly, large retrospective studies cannot deal with the question of prelabor decisions 
about mode of delivery because information about this decision was not collected. Prospective data recording 
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enables an "intention-to-treat" analysis according to planned mode of delivery. 
Although the groups were compared by an intention-to-treat analysis, their comparability cannot be guaranteed, 
as in a randomized controlled trial, and the multivariate analysis cannot completely control for all the 
confounding factors. Nonetheless, any selection bias is limited here by adjustment for factors such as educational 
level, quality of antenatal care, existence of a preliminary decision about mode of delivery, indications for the 
planned cesarean, and especially for fetal disorders. 
Several examinations are performed routinely ante-natally to help decide mode of delivery. Although evidence-
based proof of their usefulness is not available, the high rate of their performance is indicative of special 
attention to the decision. For example, comparison of PREMODA and the Term Breech Trial shows that 
physicians in the former used pelvimetry in the planned vaginal delivery group much more often (82.4% vs 
9.8%).2 Management of labor also differed between these studies. Fetal surveillance of all PREMODA cases, but 
only 33.4% of those in the Term Breech Trial, used continuous FHR. The percentage of women with an active 
phase of the second stage of labor longer than 60 minutes was only 0.2% versus 5.0% in the Term Breech 
Trial.17,18 A secondary analysis of the latter reported that an adverse perinatal outcome was associated with an 
active phase of the second stage 60 minutes or more.17 Active pushing began after the presenting part reached the 
high pelvic straits in only 3.6% of cases (information not reported in the Term Breech Trial). French guidelines 
recommend waiting to initiate active pushing in breech presentation until the presenting part reaches the outlet. 
This practice often leads to a long passive phase of the second stage of labor: 60 minutes or more in 18.1% in the 
PREMODA study versus 3.1% in the Term Breech Trial.17 Finally, only 3.8% of cases in our vaginal delivery 
group involved labor that failed to progress for more than 2 hours. 
The PREMODA results in the planned vaginal delivery group can be extrapolated only to centers where planned 
vaginal deliveries are still relatively common. In a retrospective, population-based cohort study of 100,667 
breech deliveries in California, Gilbert et al reported a high neonatal death rate among nullipara women in 
vaginal breech deliveries (OR 9.2, 95% CI [3.3,25.6]), but no information about antenatal care or labor. The 
paucity of vaginal deliveries (2.5%), however, indicates that this subgroup is probably quite particular.14
Similarly, the PREMODA results can be extrapolated only to centers that apply strict criteria before and during 
labor. The low risk in the planned vaginal delivery group may be associated with more prudent obstetric 
practices since the publication of the Term Breech Trial. According, the rate of cesarean delivery before labor for 
singleton term breech infants in France has increased from 49.0% in 1998 to 75.0% in 2003 (Enquête National 
Périnatale 2003, unpublished data), a rise also seen in the Netherlands, Australia, and New Zealand.4,19,20 
Although we do not have historic data for neonatal outcome in France, it is possible that the situation is similar 
to that observed in the Netherlands, where perinatal mortality decreased from 0.35% to 0.18% between 1998 and 
2002.21
The fetal or neonatal mortality or serious neonatal morbidity in planned vaginal deliveries in our study was 
barely one quarter that reported in the Term Breech Trial in its subgroup covering countries with low national 
perinatal mortality rates (1.6% vs 5.7%). Although some individual unfavorable outcomes in the planned vaginal 
delivery group were similar between the 2 studies (intubation for more than 24 hours, trauma), most occurred 
more frequently in the Term Breech Trial (Apgar <4, seizures, brachial plexus injuries, intraventricular 
hemorrhage, neonatal deaths, excluding lethal malformations). Neither study, however, had enough subjects to 
interpret these individual outcomes meaningfully, this is why a combined outcome was necessary. 
We did not find the excess risk associated with planned vaginal delivery that the Term Breech Trial observed for 
the subgroup covering countries with low national perinatal mortality rates (relative risk [RR] = 14.3, CI 95% 
[3.4-50.0]).2 Moreover, their recent subgroup analysis found that the prevalence of death or abnormal neurode-
velopment at 2 years did not differ according to study group (vaginal or cesarean).22 When we consider only 
deaths rather than morbidity, our study included only 1 neonatal death of a nonmalformed newborn infant and 
that 1 was in the planned cesarean group. 
Except for a 5-minute Apgar score less than 4 (n = 4 vs n = 1, respectively), none of the severe individual 
outcomes differed significantly between groups. The composite outcome was selected because it was very 
similar to that used in the Term Birth Trial and because the PREMODA scientific study considered it to be a 
thorough characterization of a poor condition in term neonates likely to result in long-term sequelae. Some other 
individual neonatal outcomes were significantly higher in the planned vaginal than in the cesarean delivery 
group. Among these individual outcomes, some cases, probably those at highest risk, were included in the 
composite variable because they met more serious criteria (ie, 16/63 of those with an Apgar score < 7; 40/58 of 
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intubated infants; 13/71 of those with trauma). The multivariate analysis was based only on the principal 
outcome variable, precisely to avoid multiple comparisons that increase the risk of observing significant 
differences by chance, especially in small groups. 
We are not the only group to have obtained results along this line: numerous recent studies that applied a 
relatively widespread policy of planned vaginal delivery, in various practice conditions, did not observe this 
excess risk.7-11 The methodology for studying policies for managing delivery of term breech infants necessarily 
differs somewhat from that for studying the biologic effect of drugs. Randomized trials assessing a management 
policy are necessary but difficult to extrapolate to other practice conditions.23,24 It is accordingly essential to 
assess a management policy in a population under conditions of everyday practice. 
CONCLUSION 
In centers where planned vaginal delivery remains a widespread practice and in complying with rigorous 
conditions before and during labor, we did not find a significant excess risk associated with planned vaginal 
delivery compared with planned cesarean for women with a singleton fetus in breech presentation at term. There 
may be a slightly higher neonatal risk associated with planned vaginal delivery but it is very different from that 
reported in the only published large randomized trial. Under the conditions discussed here, planned vaginal 
delivery of singleton fetuses in breech presentation at term remains a safe clinical option that can be offered to 
women after providing them with clear, objective, and complete information. 
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